Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6

26 May 2021

Abstract excerpt

T cells. It is likely that future treatment options will combine surface receptor and intracellular protein targets. Utilizing germline gene ablation as well as CRISPR/Cas9-mediated acute gene mutagenesis, the nuclear receptor NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) has been firmly characterized as such an intracellular immune checkpoint in effector T cells. Targeting this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34073258
DOI: 10.3390/cancers13112600

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6PMID 34073258Read ↗

Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapySemantic proximity Read ↗

Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapySemantic proximity Read ↗

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockadeSemantic proximity Read ↗

Insights into the emerging immune checkpoint NR2F6 in cancer immunitySemantic proximity Read ↗

Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunitySemantic proximity Read ↗

NR2F6 promotes the malignant progression of neuroblastoma as an indicator of poor prognosisSemantic proximity Read ↗

Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradationSemantic proximity Read ↗

Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer CellsSemantic proximity Read ↗

Nur77: a potential therapeutic target in cancerSemantic proximity Read ↗

Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer ImmunotherapySemantic proximity Read ↗

AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunitySemantic proximity Read ↗

Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.